Morgan Stanley Nuvectis Pharma, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,348 shares of NVCT stock, worth $12,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,348

Previous 10,198 76.98%

Holding current value

$12,256

Previous $64,000 78.13%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.16 - $7.23 $48,356 - $56,755	-7,850 Reduced 76.98%	2,348 $14,000
Q2 2024 Oct 17, 2024	SELL	$5.98 - $8.25 $185,338 - $255,692	-30,993 Reduced 75.24%	10,198 $64,000
Q2 2024 Aug 14, 2024	SELL	$5.98 - $8.25 $185,338 - $255,692	-30,993 Reduced 75.24%	10,198 $64,000
Q1 2024 Oct 17, 2024	BUY	$6.69 - $11.0 $207,343 - $340,923	30,993 Added 303.91%	41,191 $337,000
Q1 2024 Aug 16, 2024	BUY	$6.69 - $11.0 $122,266 - $201,036	18,276 Added 79.76%	41,191 $337,000
Q1 2024 May 15, 2024	BUY	$6.69 - $11.0 $122,266 - $201,036	18,276 Added 79.76%	41,191 $337,000
Q4 2023 Aug 16, 2024	BUY	$7.85 - $11.78 $99,828 - $149,806	12,717 Added 124.7%	22,915 $191,000
Q4 2023 Feb 13, 2024	BUY	$7.85 - $11.78 $152,572 - $228,956	19,436 Added 558.67%	22,915 $191,000
Q3 2023 Nov 15, 2023	SELL	$12.89 - $16.29 $20,933 - $26,454	-1,624 Reduced 31.82%	3,479 $44,000
Q2 2023 Aug 14, 2023	BUY	$12.62 - $18.4 $25,088 - $36,579	1,988 Added 63.82%	5,103 $81,000
Q1 2023 May 15, 2023	BUY	$7.32 - $14.37 $20,598 - $40,437	2,814 Added 934.88%	3,115 $40,000
Q4 2022 Feb 14, 2023	BUY	$6.7 - $7.74 $670 - $774	100 Added 49.75%	301 $2,000
Q3 2022 Nov 14, 2022	BUY	$7.09 - $13.0 $7 - $13	1 Added 0.5%	201 $1,000
Q2 2022 Aug 15, 2022	BUY	$7.02 - $20.44 $1,404 - $4,088	200 New	200 $2,000

Others Institutions Holding NVCT

# of Institutions

Shares Held

1.65M

Call Options Held

Put Options Held

View Full List

About Nuvectis Pharma, Inc.

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $76.4M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

More about NVCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account